Evaluation of the relationship of the amount of ascites as measured quantitatively using computed tomography with chemotherapy toxicity in patients with ovarian cancer

In this study, it was planned to investigate the effects of ascites and sarcopenia on treatment toxicity, disease free survival (DFS) and disease specific survival (DSS) times in a population of patients with stage 3–4 ovarian cancer. In this retrospective study that include 80 patients treated and followed-up for advanced stage ovarian cancer in a university hospital between 2012–2019, ascites volumes and sarcopenia indices of the patients were calculated by computed tomography from medical patient records, and their clinico-pathologic characteristics as well as laboratory variables were reviewed. The median survival was 30.10 ± 2.85 months for the patients with ascites and 54.26 ± 4.16 months without ascites (p < 0.001). The duration of DSS was found to be negatively affected in patients with ascites (Hazard Ratio (HR): 3.048), prognostic nutritional index (PNI) <47.5 (HR: 2.528), platelet (PLT) >338,000 (HR: 1.936), lactate dehydrogenase (LDH) value >320 (HR: 1.624), albumin value <4 (HR: 1.849). When factors that are found to have a significant relationship with DSS were assessed according to multivariate Cox regression analysis, the presence of ascites was identified as an independent risk factor associated with DSS (p: 0.004). The risk of developing grade 2 or 3 neutropenia, anemia and thrombocytopenia is significantly increased following the first chemotherapy course in patients with ascites when compared to those without ascites (p: 0.006). The presence of ascites in patients with ovarian cancer is a risk factor associated with chemotherapy toxicity and reduced survival.

Ascites; Chemotherapy toxiticy; Ovarian cancer; Sarcopenia

[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021; 71: 7–33.

[2] Jiang R, Zhu J, Kim JW, Liu J, Kato K, Kim HS, et al. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. Journal of Gynecologic Oncology. 2020; 31: e86.

[3] Ni J, Zhang L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Management and Research. 2020; 12: 5597–5605.

[4] Anjanappa M, Corden M, Green A, Roberts D, Hoskin P, McWilliam A, et al. Sarcopenia in cancer: risking more than muscle loss. Technical Innovations & Patient Support in Radiation Oncology. 2020; 16: 50–57.

[5] Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. British Journal of Cancer. 2020; 123: 9–16.

[6] Oriuchi N, Nakajima T, Mochiki E, Takeyoshi I, Kanuma T, Endo K, et al. A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Japanese Journal of Clinical Oncology. 2005; 35: 386–390.

[7] Ubachs J, Ziemons J, Minis‐Rutten IJG, Kruitwagen RFPM, Kleijnen J, Lambrechts S, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta‐analysis. Journal of Cachexia, Sarcopenia and Muscle. 2019; 10: 1165–1174.

[8] Weir CB, Jan A. BMI classification percentile and cut off points. StatPearls Publishing: Treasure Island (FL). 2021.

[9] Arshad U, Taubert M, Seeger-Nukpezah T, Ullah S, Spindeldreier KC, Jaehde U, et al. Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. BMC cancer. 2021; 21: 719.

[10] Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, et al. The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer. BMC Cancer. 2018; 18: 883.

[11] Eisenhauer EA TP, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer. 2009; 45: 228–247.

[12] Pin F, Couch ME, Bonetto A. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Current Opinion in Supportive & Palliative Care. 2018; 12: 420–426.

[13] Purcell SA, Kok DE, Ketterl T, Garcia MB, Joffe L, Brown JC, et al. Pharmacokinetics of cancer therapeutics and energy balance: the role of diet intake, energy expenditure, and body composition. JNCI Monographs. 2023; 2023: 3–11.

[14] Saygili U, Guclu S, Uslu T, Erten O, Dogan E. The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. International Journal of Gynecological Cancer. 2002; 12: 438–442.

[15] Ayhan A, Gultekin M, Taskiran C, Dursun P, Firat P, Bozdag G, et al. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. International Journal of Gynecologic Cancer. 2007; 17: 68–75.

[16] Quan Q, Zhou S, Liu Y, Yin W, Liao Q, Ren S, et al. Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer. Journal of Obstetrics and Gynaecology Research. 2021; 47: 1527–1535.

[17] Feigenberg T, Clarke B, Virtanen C, Plotkin A, Letarte M, Rosen B, et al. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. BioMed Research International. 2014; 2014: 367103.

[18] Anjanappa M, Corden M, Green A, Roberts D, Hoskin P, McWilliam A, et al. Sarcopenia in cancer: risking more than muscle loss. Technical Innovations & Patient Support in Radiation Oncology. 2020; 16: 50–57.

[19] Allanson ER, Peng Y, Choi A, Hayes S, Janda M, Obermair A. A systematic review and meta-analysis of sarcopenia as a prognostic factor in gynecological malignancy. International Journal of Gynecologic Cancer. 2020; 30: 1791–1797.

[20] Bruno KDA, Sobreira da Silva MJ, Chaves GV. Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma. Acta Oncologica. 2021; 60: 1611–1620.

[21] Staley SA, Tucker K, Newton M, Ertel M, Oldan J, Doherty I, et al. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecologic Oncology. 2020; 156: 695–700.

[22] Del Grande M, Rizzo S, Nicolino GM, Colombo I, Rossi L, Manganaro L, et al. Computed tomography-based body composition in patients with ovarian cancer: association with chemotoxicity and prognosis. Frontiers in Oncology. 2021; 11: 718815.